We are currently studying the potential of two additional product candidates in preclinical studies.
The first candidate, VIB1116, is a monoclonal antibody (mAb) designed to decrease the number and function of antigen-presenting dendritic cells. We expect to conduct preclinical toxicology studies to enable a submission of an Investigational New Drug application to the FDA in the second half of 2020.
The second candidate is a mAb cytokine fusion protein designed to inhibit inflammatory responses. We are currently conducting preclinical efficacy studies of this candidate in animal models.